Insmed (NASDAQ:INSM) Hits New 12-Month High – Still a Buy?

Insmed, Inc. (NASDAQ:INSM) shares hit a new 52-week high during trading on Friday . The company traded as high as $197.45 and last traded at $196.03, with a volume of 1060829 shares traded. The stock had previously closed at $190.96.

Analyst Ratings Changes

Several research analysts have recently commented on the company. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Insmed in a research note on Wednesday, October 8th. TD Cowen raised their target price on shares of Insmed from $154.00 to $193.00 and gave the stock a “buy” rating in a research note on Thursday, October 2nd. The Goldman Sachs Group upped their price target on shares of Insmed from $196.00 to $225.00 and gave the stock a “buy” rating in a research report on Friday, October 31st. William Blair assumed coverage on shares of Insmed in a research note on Wednesday, August 20th. They issued an “outperform” rating for the company. Finally, UBS Group lifted their target price on shares of Insmed from $194.00 to $223.00 and gave the company a “buy” rating in a research note on Friday, October 31st. Nineteen investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $173.29.

Insmed Trading Up 1.2%

The stock has a market cap of $41.21 billion, a P/E ratio of -33.84 and a beta of 1.05. The stock’s 50-day moving average is $162.35 and its two-hundred day moving average is $120.69. The company has a debt-to-equity ratio of 0.45, a current ratio of 6.68 and a quick ratio of 6.33.

Insmed (NASDAQ:INSM) last announced its quarterly earnings results on Thursday, October 30th. The biopharmaceutical company reported ($1.75) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.35) by ($0.40). Insmed had a negative net margin of 259.82% and a negative return on equity of 195.37%. The company had revenue of $142.34 million during the quarter, compared to the consensus estimate of $114.33 million. During the same quarter in the prior year, the firm posted ($1.27) earnings per share. The business’s revenue was up 52.4% on a year-over-year basis. Insmed has set its FY 2025 guidance at EPS. Equities research analysts anticipate that Insmed, Inc. will post -4.56 EPS for the current year.

Insider Activity at Insmed

In related news, CEO William Lewis sold 6,865 shares of the firm’s stock in a transaction on Monday, August 18th. The shares were sold at an average price of $128.40, for a total value of $881,466.00. Following the completion of the transaction, the chief executive officer directly owned 233,924 shares of the company’s stock, valued at approximately $30,035,841.60. This trade represents a 2.85% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, COO Roger Adsett sold 25,000 shares of the company’s stock in a transaction on Tuesday, August 19th. The shares were sold at an average price of $127.58, for a total transaction of $3,189,500.00. Following the sale, the chief operating officer directly owned 105,637 shares in the company, valued at approximately $13,477,168.46. The trade was a 19.14% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold 209,787 shares of company stock valued at $32,248,149 in the last 90 days. 3.00% of the stock is currently owned by insiders.

Institutional Trading of Insmed

Hedge funds have recently made changes to their positions in the business. Cullen Frost Bankers Inc. boosted its holdings in shares of Insmed by 164.9% in the 1st quarter. Cullen Frost Bankers Inc. now owns 355 shares of the biopharmaceutical company’s stock worth $27,000 after purchasing an additional 221 shares during the period. ORG Partners LLC boosted its stake in Insmed by 220.2% during the second quarter. ORG Partners LLC now owns 285 shares of the biopharmaceutical company’s stock worth $28,000 after buying an additional 196 shares during the period. Hilltop National Bank bought a new position in Insmed during the second quarter valued at $28,000. Stone House Investment Management LLC purchased a new stake in shares of Insmed in the third quarter valued at $29,000. Finally, SBI Securities Co. Ltd. lifted its holdings in shares of Insmed by 404.9% in the 3rd quarter. SBI Securities Co. Ltd. now owns 207 shares of the biopharmaceutical company’s stock worth $30,000 after acquiring an additional 166 shares during the last quarter.

About Insmed

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed’s first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.